This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bernabeu-Wittel, M., Pichardo, C., Garcia-Curiel, A., Pachon-Ibanez, M.E., Ibanez-Martinez, J., Jimenez-Mejias, M.E., Pachon, J. 2005. Phamacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or a combination with amikacin for the treatment of experimental multi-resistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect. 11:319–25.
Druilhe, P., Hagan, P., Rook, G.A. 2002. The importance of models of infection in the study of disease resistance. Trends Microbiol. 10:S38–46
Erridge, C., Moncayo-Nieto, O.L., Morgan, R., Young, M., Poxton, I.R. 2007. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via toll-like receptor 4 signalling. J Med Microbiol. 56:165–71.
Houhamdi, L., Raoult, D. 2006. Experimental infection of human body lice with Acinetobacter baumannii. Am J Trop Med Hyg. 74:526–31.
Joly-Guillou, M.L. 1999. Importance de l'inoculum microbien dans les modèles expérimentaux: impact sur l'antibiothérapie. Antibiotiques. 1:77–81.
Joly-Guillou, M.L., Wolff, M., Farinotti, R., Bryskier, A., Carbon, C. 2000. In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. J Antimicrob Chemother. 46:827–30.
Joly-Guillou, M.L., Wolff, M., Pocidalo, J.J., Walker, F., Carbon, C. 1997. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the post-antibiotic effect of imipenem. Antimicrob Agents Chemother. 41:345–51.
Knapp, S., Wieland, C.W., Florquin, S., Panthophlet, R., Dijkshoorn, L., Tshimbalanga, N., Arika, S., Van Der Poll, T. 2006. Differential roles of CD14 and toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Am J Respir Crit Care Med. 173:122–29.
Montero, A., Ariza, J., Corbella, X., Doménech, A., Cabellos, C., Ayats, J., Tubau, F., Ardanuy, C., Gudiol, F. 2002. Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother. 46:1946–52.
Montero, A., Ariza, J., Corbella, X., Domenech, A., Cabellos, C., Ayats, J., Tubeau, F., Borraz, C., Gudiol, F. 2004. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother. 54:1085–91.
Obana, Y., Nishino, T., Tanino, T. 1985. In-vitro and in-vivo activities of antimicrobial agents against Acinetobacter calcoaceticus. J Antimicrob Chemother. 15:441–48.
Obana, Y. 1986. Pathogenic significance of Acinetobacter calcoaceticus: analysis of experimental infection in mice. Microbiol Immunol. 30:645–57.
Pachon-Ibanez, M.E., Fernandez-Cuenca, F., Docobo-Perez, F., Pachon, J., Pascual, A. 2006. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother. 58:689–92.
Pantopoulou, A., Giamarellos-Bourboulis, E.J., Raftogannis, M., Tsaganos, T., Dontas, I., Koutoukas, P., Baziaka, F., Giamarellou, H., Perrea, D. 2007. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Intern J Antimicrob Agents. 29:51–55.
Rathinavelu, S., Zavros, Y., Merchant, J.L. 2003. Acinetobacter lwoffii infection and gastritis. Microbes Infect. 5:651–57.
Renckens, R., Roelofs, J.J.T.H., Knapp, S., De Vos, A.F., Florquin, S., Van Der Poll, T. 2006. The acute-phase response and serum amyloid A inhibit the inflammatory response to Acintobacter baumannii pneumoniae. J Infect Dis. 193:187–95.
Rodriguez-Hernandez, M.J., Cuberos, L., Pichardo, C., Caballero, F.J., Moreno, I., Jimenez-Mejias, M.E., Garcia-Curiel, A., Pachon, J. 2001. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother. 47:479–82.
Rodriguez-Hernandez, M.J., Pachon, J., Pichardo, C., Cuberos, L., Ibanez-Martinez, J., Garcia-Curiel, A., Caballero, F.J., Moreno, I., Jimenez-Mejias, M.E. 2000. Iimpenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother. 45:493–501.
Wolff, M., Joly-Guillou, M.L., Farinotti, R., Carbon, C. 1999. In vivo efficacies of combinaisons of β- lactams, β-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob agents Chemother. 43:1406–11.
Wiles, S., Hanage, W.P., Frankel, G., Robertson, B. 2006. Modelling infectious disease – time to think outside the box? Nat Rev Microbiol. 4:307–12.
Zavros, Y., Rieder, G., Ferguson, A., Merchant, J.L. 2002. Gastridis and hypergastrinemia due to Acinetobacter lwoffii in mice. Infect Immun. 70:2630–39.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Joly-Guillou, M.L., Wolff, M. (2008). Experimental Models of Acinetobacter Infection. In: Bergogne-Bérézin, E., Friedman, H., Bendinelli, M. (eds) Acinetobacter Biology and Pathogenesis. Infectious Agents and Pathogenesis. Springer, New York, NY. https://doi.org/10.1007/978-0-387-77944-7_10
Download citation
DOI: https://doi.org/10.1007/978-0-387-77944-7_10
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-77943-0
Online ISBN: 978-0-387-77944-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)